Day 23 is less about one announcement than about trajectory. The FDA's compounding clarification has not been walked back, and the agency's compliance posture remains enforcement-forward as warning-letter volume and naming continue to accumulate. [1][2]

The paper's Apr 23 GLP one read separated label-language changes from access economics. That split still holds. Removing one warning line does not erase risk heterogeneity across products, and it does not grant open-ended latitude to compounders outside shortage-boundary logic. [1] The system now has two simultaneous facts: access demand is huge, and enforcement tolerance is narrower.

X is where the second-order debate is louder - especially around whether semaglutide psychiatric-event patterns in pharmacovigilance data should alter payer or prescribing assumptions at the margin. MSM is still publishing the cleaner regulatory story. The paper's position remains that both streams matter: enforcement shapes supply architecture, while post-market signal discussions shape liability and clinical confidence. Day 23 keeps both tracks live.

-- NORA WHITFIELD, Chicago